Summary Twenty-seven of 152 patients (18%) with progressing hormone resistant prostate cancer had normal serum levels of prostate specific antigen (PSA < 1O jig l-), when referred for secondary treatment. PSA was significantly correlated with the extent of skeletal metastases (R: 0.35) and the levels of hemoglobin (R: -0.19) and serum alkaline phosphatase (R: 0.30).
In a multivariate Cox regression analysis the survival of the 152 patients was not correlated with the PSA level but with the patients performance status, the level of hemoglobin, and the time between primary hormone treatment and relapse.
The lack of serum PSA to predict survival may be explained by a heterogeneous composition of hormone resistant prostate cancer as regards differentiated and/or PSA producing vs undifferentiated and/or PSA non-producing cells.
Several authors have shown that prostate specific antigen (PSA) mirrors the initial tumour burden and the development of the disease during and after primary treatment of prostate cancer (Emtage et al., 1987; Hetherington et al., 1988; Stamey & Kabalin, 1989 (Waehre et al., 1991 The median survival for all patients was 10 months from referral to the NRH and PSA measurement with no significant differences between the four groups ( Figure 1 ). If Group A was combined with Group D (Figure 2 ) the survival of Group (A + D) tended to be worse than that for the combined Group (B + C) (P = 0.12).
The following parameters were analysed by the backwards stepwise Cox regression analysis, as concern their impact on survival: Performance status, Hgb, hormone dependent interval, creatinine, PSA, APHOS, EOD score. Only the 3 first variables proved to be significantly independent prognostic parameters (P < 0.002). The EOD score was a 4th almost significant prognostic parameter (P = 0.10). The addition of PSA to the three first mentioned parameters did not contribute to a better prediction of survival (P = 0.20). (Emtage et al., 1987; Hetherington et al., 1988; Stamey & Kabalin, 1989; Stamey et al., 1989a; Stamey et al., 1989b; Stamey et al., 1989c studies the reduction of PSA during androgen-suppressive treatment was found to be more pronounced than the decrease of the tumour burden (Csapo et al., 1988) . One explanation for the limited correlation between PSA and assessed tumour volume would be that the tumour manifestations in hormone resistant disease consist of relatively large amounts of undifferentiated and probably PSA non-producing cells (Bruchovsky et al., 1987; Isaacs, 1984) . Such a finding might mirror a particularly aggressive tumour biology. The relative short hormone dependent interval (median 12 months) for Group A supports this view. Normal PSA in hormone resistant prostatic cancer may thus be another sign of high biological aggressiveness. The relatively low coefficient of correlation between PSA and skeletal EOD (R: 0.35) may be due to not-detected tumour manifestations elsewhere in the patient. An individual patient with hormone resistant prostate cancer may present with large soft tissue tumour masses which remain undetected by routine examination (computer tomogrpahy usually not performed), but contribute significantly to the total tumour burden and probably to the individual's PSA level.
The PSA level in a patient with hormone resistant prostate cancer seems to be dependent on the balance of several conditions: The often undetected true tumour burden and the quantitative relation between PSA non-producing undifferentiated cells and PSA-producing more differentiated cells. Normal or only slightly elevated PSA values may reflect limited disease or, as probably the case in most of our patients, may be correlated with larger metastases from a biologically aggressive and rapidly progressing cancer mainly consisting of PSA non-producing cells. The latter patients would theoretically have a similar prognosis as patients with high PSA values usually correlated with extensive disease. This was the background for comparison of the survival for the combined Group (A + D) with that for Group (B + C), where a tendency of improved prognosis was found for Group (B + C). Leo et al. (1991) discuss a 3rd explanation for low PSA levels in patients with short survival times. Hormone treatment may decrease the cellular PSA expression without reducing the tumour cell's viability.
Due to the above heterogeneity of the internal composition of tumour manifestations in hormone resistant prostate cancer and the often unknown true tumour burden, patients' survival seems better to be related to indirect parameters as Hgb and performance status than to PSA, APHOS or bone scan involvement. It is therefore understandable that the former parameters represent independent prognostic parameters, whereas PSA does not. The time between the initial hormone treatment and relapse (hormone dependent interval) is another significant parameter, probably mirroring the biological aggressiveness of the individual tumour.
Also in other studies Hgb, performance status and hormone control time have been found to be independent prognostic parameters Berry et al., 1979; Emrich et al., 1985; Manni et al., 1988) . In one of our previous studies also creatinine was a significant independent parameter (Fossa et al., 1991) . We have no explanation why this parameter was not an independent parameter in the present study except from noting a lower frequency of patients with elevated creatinine, 11%.
In the present study about PSA the level did not have prognostic value if measured shortly after symptomatic progression of prostate cancer. This does not exclude that PSA measurements are without clinical significance in these patients. Any larger PSA increase most likely mirrors disease progression in spite of ongoing treatment and the degree of increase may reflect the rate of progression, thus probably bearing prognostic impact. This hypothesis cannot be tested in the present patient series, as no PSA levels were available prior to their admission to the NRH. Furthermore, most of the patients were neither followed-up by the NRH nor had PSA values after their palliative treatment at this institution.
In conclusion, in hormone resistant prostatic cancer serum PSA levels are correlated with the bone scan involvement, Hgb and APHOS, though the correlation coefficients are relatively low. However, 18% of the patients had normal serum PSA values in spite of advanced disease. PSA values analysed about 2 months after subjective progression of hormone resistant prostate cancer do not predict patients' survival.
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